Valproic Acid and Breast Cancer: State of the Art in 2021 1
Recent studies reported a possible effect of VPA against particular types of cancers
VPA has shown potent antitumor effects in a variety of in vitro and in
124263 Corpus ID: 267714059; Lenvatinib-valproic acid self nanoemulsifying preconcentrate for the treatment of liver cancer
Valproic acid (VPA) inhibits HDACs activity and shows anti-cancer effect through distinct mechanisms of action
Main methods: The inhibitory effect of valproic acid on breast cancer in vivo and in vitro was evaluated by cellular and animal
Valproate (VPA) is a well-characterized histone deacetylase inhibitor with anti-neoplastic properties
It was reported that valproic acid (VPA, a histone deacetylase inhibitor) can sensitize cancer cells to hydroxyurea (HU, a ribonucleotide reductase inhibitor) for chemotherapy, although the mechanism of VPA-induced HU sensitization is unclear
It has recently been recognized as a promising anticancer drug
, 2018)
A tissue microarray of VPA-treated and untreated tumor xenografts and cell lines of human PCa (LNCaP, C4-2, DU145, and PC-3) were
These include alteration of estrogen receptor status, modulation of the tumor immune response, alteration of metastatic potential, induction of cell death, and induction
To determine whether these changes in growth are recapitulated consistently in human cells, we compared the effect of Chiron99021 and Valproic acid on HAB92 colorectal cancer cells (a derivative Prostate cancer (PCa) is the most frequent cancer in men
doi: 10